volume 84, issue 10, P1534-1548 2016
DOI: 10.1002/prot.25096
View full text
|
Sign up to set email alerts
|
Share

Abstract: ABSTRACTSoluble guanylate cyclase (sGC), the main target of nitric oxide (NO), has been proven to have a significant role in coronary artery disease, pulmonary hypertension, erectile dysfunction, and myocardial infarction. One of its agonists, BAY 41-2272 (Riociguat), has been recently approved for treatment of pulmonary arterial hypertension (PHA), while some others are in clinical phases of development. However, the location of the binding sites for the two known types of agonists, hemedependent stimulators…

Expand abstract